-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25

Benzinga·08/05/2026 17:14:55
Listen to the news
Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $23 to $25.